St.Gallen International Breast Cancer Conference

A team of researches sought to assess the effectiveness of breast cancer surveillance among patients with BRCA1/2 mutations.

A team of investigators who conducted a meta-analysis to evaluate the safety and efficacy of tyrosine kinase inhibitors in patients with HER-2 positive breast cancer with brain metastases presented their findings at the 17th St. Gallen International Breast Cancer Conference.

A team of investigators conducted a meta-analysis to evaluate the efficacy and safety of dual HER2 blockade with a pertuzumab-based regimen in patients previously exposed to anti-HER2 treatment.

Final results of the ExteNET study were presented at the 17th St. Gallen International Breast Cancer Conference 2021.

Researchers report findings from the CONTROL trial at the 17th St. Gallen International Breast Cancer Conference.

A team of investigators conducted a retrospective analysis to evaluate outcomes of patients with early breast cancer who were undergoing neoadjuvant chemotherapy.

Subcutaneous trastuzumab has the potential to reduce the number of regular clinic visits and the amount of time a patient spends in the hospital or clinic.

Investigators surveyed patients in the international INSPIRE registry to assess the impact of adjuvant endocrine therapy on health-related quality of life in women undergoing nipple-sparing mastectomy for breast cancer.

The LAVENDER study evaluated the safety and tolerability of ABP 980, a biosimilar approved for patients with metastatic breast cancer, early breast cancer, adjuvant breast cancer, and metastatic gastric cancer.

A team of investigators compared outcomes in patients with metaplastic breast cancer compared with those with ductal triple-negative breast cancer.